TWI PHARMACEU8TICALS INC

Company Introduction

Location: Taiwan

Nature of Business: Manufacturer (Factory)

Detailed Description:

TWI Pharmaceuticals Inc. is a pharmaceutical company based in Taiwan that specializes in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. They are involved in the entire lifecycle of drug development, from R&D to production and distribution, indicating their primary role as a manufacturer and a comprehensive pharmaceutical enterprise.

TWI Pharmaceuticals Inc. (Taiwan) manufactures or sells the following products and pipeline candidates:

Taigexyn (Nemonoxacin)

Description: An oral and intravenous broad-spectrum antibiotic.

Indications: Approved for the treatment of community-acquired pneumonia (CAP).

Finafloxacin (TG-873870)

Description: A topical fluoroquinolone antibiotic ear drop formulation.

Indications: Approved for the treatment of acute otitis externa (AOE).

Burixafor (TG-0054)

Description: A CXCR4 antagonist.

Indications: In clinical development for stem cell mobilization in hematopoietic stem cell transplantation and for peripheral T-cell lymphoma (PTCL).

Crolanerect (TG-2349)

Description: A novel serotonin 5-HT4 receptor partial agonist.

Indications: In clinical development for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

TG-1000

Description: A broad-spectrum antiviral drug.

Indications: In preclinical development for various viral infections.

TG-1008

Description: A topical antifungal drug.

Indications: In preclinical development for fungal infections.